Carboxamide HPK1 Inhibitors for Antitumor Immunity Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that modulate the activity of hematopoietic progenitor kinase 1 (HPK1) to enhance antitumor immunity and address autoimmune diseases, as existing treatments are inadequate in effectively targeting this kinase.
Innovation Solution
Development of carboxamide compounds that inhibit HPK1 activity, which are administered to individuals to modulate immune cell functions and treat related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used to target HPK1, then treatment coverage is provided, but effectiveness in enhancing antitumor immunity and addressing autoimmune diseases is inadequate
Solution Approach 1:
The patent employs parameter changes by modifying chemical structure parameters to develop novel carboxamide compounds with optimized HPK1 inhibition properties. The compounds feature specific structural parameters including a carboxamide group, aromatic rings, and various substituents that can be adjusted to enhance binding affinity and selectivity for HPK1, thereby improving treatment effectiveness while maintaining targeted action against the kinase.
2Adaptability or versatility
If new compounds are developed to specifically target HPK1, then adaptability to enhance antitumor immunity is improved, but treatment effectiveness may be reduced due to lack of clinical validation
Solution Approach 1:
The patent applies preliminary action by conducting extensive in vitro and in vivo characterization of the carboxamide compounds before clinical application. This includes preliminary assessment of HPK1 inhibition potency, selectivity against other kinases, pharmacokinetic properties, and preliminary efficacy in preclinical tumor models and autoimmune disease models, thereby establishing a foundation for reliable clinical effectiveness.
Solution Approach 2:
The patent incorporates feedback mechanisms through iterative optimization of compound structures based on biological activity data. Structural parameters of the carboxamide compounds are adjusted based on feedback from HPK1 binding assays, cell-based functional assays, and in vivo efficacy studies, allowing continuous improvement of both targeting capability and treatment effectiveness.
Data Source
AI summary
Disclosed are compounds of Formula (I′) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.